A setting of small-cell lung cancer (SCLC) that has not seen its standard-of-care treatment change since the 1980s is poised to enter the immunotherapy era based on positive results from a study using AstraZeneca PLC’s PD-L1 inhibitor Imfinzi (durvalumab). But while it marks a major advance, the track record of adding AstraZeneca’s CTLA-4 inhibitor Imjudo (tremelimumab-actl) has not shown the same level of success.
ASCO: AstraZeneca’s ADRIATIC Passes One Test, With One More To Go
The results for Imfinzi mark the first significant advance in LS-SCLC in four decades, but will the combination with Imjudo succeed after flopping in CASPIAN?
More from ASCO
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.